Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys

Obstetrics and Gynecology

Volumn 96, Issue 2, 2000, Pages 250-255

  Adams, Michael R ^a   Anthony, Mary S ^a   Manning, James M ^b   Golden, Deborah L ^a   Parks, John S ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WILLIAM PATERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; MONKEY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CONTRACEPTIVES, ORAL, COMBINED; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; LEVONORGESTREL; LIPOPROTEINS; MACACA FASCICULARIS; PROGESTERONE CONGENERS; RANDOM ALLOCATION;

EID: 0033922022     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(00)00891-7     Document Type: Article

References (40)

1. Chasan-Taber L., Stampfer M.J. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 128:1998;467-477.
2. Stampfer M.J., Willett W.C., Colditz G.A., Speizer F.E., Hennekens C.H. A prospective study of past use of oral contraceptives and cardiovascular diseases. N Engl J Med. 319:1988;1313-1317.
3. Sidney S., Siscovick D.S., Petitti D.B., Schwartz S.M., Quesenberry C.P., Psaty B.M., et al. Myocardial infarction and use of low-dose oral contraceptives. A pooled analysis of two US studies. Circulation. 98:1998;1058-1063.
4. Engel H.J., Engel E., Lichtlen P.R. Coronary atherosclerosis and myocardial infarction in young women role of oral contraceptives . Eur Heart J. 4:1983;1-8.
5. Adams M.R., Clarkson T.B., Koritnik D.R., Nash H.A. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril. 47:1987;1010-1018.
6. Clarkson T.B., Shively C.A., Morgan R.M., Koritnik D.R., Adams M.R., Kaplan J.R. Oral contraceptives and coronary artery atherosclerosis in cynomolgus monkeys. Obstet Gynecol. 75:1990;217-222.
7. Allain C.C., Poon L.S., Chan C.S.G., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem. 20:1974;470-475.
8. Fossati P., Principe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 28:1982;2077-2080.
9. United States Dept of Health, Education and Welfare publication NIH 75-628 [revised 1982]. Lipid Research Clinics Program. Manual of laboratory operations: Lipid and lipoprotein analysis. Bethesda, MD: National Institutes of Health, 1984.
10. Manning J.M., Edwards I.J., Wagner W.D., Wagner J.D., Adams M.R., Parks J.S. Effects of contraceptive estrogen and progestin on the atherogenic potential of plasma LDL in cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 17:1997;1216-1223.
11. Auerbach B.J., Parks J.S., Applebaum-Bowden D. A rapid and sensitive micro-assay for the enzymatic determination of plasma and lipoprotein cholesterol. J Lipid Res. 31:1990;738-742.
12. Rudel L.L., Pitts L.L. II, Nelson C.A. Characterization of plasma low density lipoproteins of nonhuman primates fed dietary cholesterol. J Lipid Res. 18:1977;211-222.
13. Sorci-Thomas M., Wilson M.D., Johnson F.L., Williams D.L., Rudel L.L. Studies on the expression of genes encoding apolipoprotein B100 and B48 and the low density lipoprotein receptor in nonhuman primates. J Biol Chem. 264:1989;9039-9045.
14. Koritnik D.L., Rudel L.L. Measurement of apolipoprotein A-I concentration in nonhuman primate plasma by enzyme-linked immunosorbent assay (ELISA). J Lipid Res. 24:1983;1639-1645.
15. Nichols A.V., Krauss R.M., Musliner T.A. Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol. 128:1986;417-432.
16. Verdery R.B., Benham D.F., Baldwin H.L., Goldberg A.V. Measurement of normative HDL subfraction cholesterol levels by Gaussian summation analysis of gradient gels. J Lipid Res. 30:1989;1085-1090.
17. Neeley W.E. Simple automated determination of serum or glucose by a hexokinase-glucose-6-phosphate dehydrogenase method. Clin Chem. 18:1972;509-515.
18. Meis P.J., Kaplan J.R., Koritnik D.R., Rose J.C. Effects of gestation on glucose tolerance and plasma insulin in cynomolgus monkeys. Am J Obstet Gynecol. 144:1982;543-545.
19. Wagner J.D., Adams M.R., Schwenke D.C., Clarkson T.B. Oral contraceptive treatment decreases arterial LDL degradation in female cynomolgus monkeys. Arterioscler Thromb. 12:1992;716-723.
20. Farley T.M.M., Collins J., Schlesselman J.J. Hormonal contraception and risk of cardiovascular disease. Contraception. 57:1998;211-230.
21. Bellinger D.A., Williams J.K., Adams M.R., Honoré E.K., Bender D.E. Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model. Arterioscler Thromb Vasc Biol. 18:1998;92-99.
22. Wagner J.D., Clarkson T.B., St Clair R.W., Schwenke D.C., Shively C.A., Adams M.R. Estrogen and progesterone replacement therapy reduces LDL accumulation in the coronary arteries of surgically postmenopausal cynomolgus monkeys. J Clin Invest. 88:1991;1995-2002.
23. Libby P., Hansson G.K. Involvement of the immune system in human atherogenesis Current knowledge and unanswered questions . Lab Invest. 64:1991;5-15.
24. Ross R. The pathogenesis of atherosclerosis A perspective for the 1990's . Nature. 362:1993;801-809.
25. Pervin S., Singh R., Rosenfeld M.E., Navab M., Chaudhuri G., Nathan L. Estradiol suppresses MCP-1 expression in vivo. Implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 18:1998;1575-1582.
26. Frazier-Jessen M.R., Kovacs E.J. Estrogen modulation of JE/monocyte chemoattractant protein-1 expression in murine macrophages. J Immunol. 154:1995;1838-1845.
27. Nakai K., Itoh C., Hotta K., Itoh T., Yoshizumi M., Hiramori K. Estradiol-17 beta regulates the induction of VCAM-1 mRNA expression by interleukin-1 in human umbilical vein endothelial cells. Life Sci. 54:1994;221-227.
28. Stein B., Yang M.X. Repression of the interleukin-6 promoter by estrogen is mediated by NF-kB and C/EBP-beta. Mol Cell Biol. 15:1995;4971-4979.
29. Girasole G., Jilka R.L., Passeri G., Boswell S., Boder G., Williams D.C., et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro A potential mechanism for the antiosteoporotic effect of estrogens . J Clin Invest. 89:1992;883-891.
30. Caulin-Glaser T., Watson C.A., Pardi R., Bender J.R. Effects of 17 beta-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 98:1996;36-42.
31. Azia K.E., Wakefield D. Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by beta-estradiol, progesterone, and dexamethasone. Cell Immunol. 167:1996;79-85.
32. Williams J.K., Adams M.R., Klopfenstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 81:1990;1680-1687.
33. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short-term administration of estrogen and responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 20:1992;452-457.
34. Williams J.K., Honoré E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 24:1994;1757-1761.
35. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Estrogen modulates coronary artery vasomotor responses in postmenopausal women with early atherosclerosis. Am J Cardiol. 73:1994;951-952.
36. Rosano G.M.C., Sarrel P.M., Poole-Wilson P.A., Collins P. Oestrogen improves exercise-induced myocardial ischaemia in female patients with coronary artery disease. Lancet. 342:1993;133-136.
37. Miyagawa K., Rosch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 3:1997;324-327.
38. Maseri A., Severi S., DeNes M., L'Abbate A., Chierchia S., Marzilli M., et al. "Variant" angina: One aspect of a continuous spectrum of vasospastic myocardial ischemia. Pathogenetic mechanisms, estimated incidence, and clinical and coronary arteriographic findings in 138 patients. Am J Cardiol. 42:1978;1019-1035.
39. Maseri A., Severi S., DeNes M., L'Abbate A., Chierchia S., Marzilli M., et al. Coronary vasospasm as a possible cause of myocardial infarction A conclusion derived from the study of "preinfarction" angina . N Engl J Med. 299:1978;1271-1277.
40. Roberts W.C., Durry R.C., Isner J.M. Sudden death in Prinzmetal's angina with coronary spasm documented by angiography Analysis of three necropsy patients . Am J Cardiol. 50:1982;203-210.